Project Grant R03HL180786
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will provide $156,340.00 over 5 years, starting on June 15, 2025, to Connecticut Children's Medical Center to develop and test a provider-focused intervention to improve health outcomes in pediatric sickle cell disease. The key products and services to be delivered under this award include: Literature reviews on provider communication and health outcomes in pediatric...
- This Project Grant award of $154,796.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Vanderbilt University Medical Center aims to use non-invasive neuroimaging techniques to investigate cerebral oxygen utilization in patients with sickle cell disease. The goal is to develop biomarkers that can be used to assess ischemic risk and evaluate the impact of emerging treatments on brain health. The project will explore how abnormal...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $122,840 project grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the Medical College of Wisconsin (MCW) to support "Patient-Oriented Research Mentoring for the Investigation of Acute and Chronic Sickle Cell Disease Pain". The goal of this 5-year grant, awarded on August 1, 2025, is for Dr. Amanda Brandow, a mid-career physician-scientist, to enhance her mentoring skills and develop the next...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research CFDA program (93.837), awarded a $483,852 Project Grant to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to develop a platform technology for measuring the kinetics and equilibrium concentration of sickle hemoglobin polymerization in single red blood cells. This technology aims to support drug potency assessment and patient risk stratification for sickle...
- The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded The Ohio State University a $765,931 Project Grant on August 22, 2025. This grant will fund a multi-center hybrid effectiveness-implementation trial to assess the delivery of patient-facing, evidence-based guidelines for sickle cell disease (SCD) through a mobile health (mHealth) application and educational booklets. The goal is to improve knowledge and adherence to...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides funding of $2,968,063.02 to the Children's Research Institute to conduct a randomized, double-blind, placebo-controlled Phase 2 clinical trial of intravenous citrulline for treating vaso-occlusive crisis in sickle cell disease. The study aims to determine if the administration of citrulline, which plays a role in nitric oxide production, can lead to...
- This federal Project Grant award of $195,846.00, awarded on August 1, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research), supports a prospective cohort study to investigate the role of blood-brain barrier (BBB) disruption on ischemic brain injury and cognitive impairment in sickle cell disease (SCD). The key objectives are to: 1) assess BBB permeability in SCD patients compared to healthy controls, 2) investigate thromboinflammatory pathways...
- This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is providing $731,130 to the Children's Hospital Medical Center to conduct a study titled "Improving Medication Adherence Using an Adaptive mHealth Intervention in Adolescents with Asthma". The study aims to evaluate the effectiveness of a stepped-care mHealth intervention for improving adherence to daily inhaled corticosteroids in adolescents with asthma. The...
- This $146,013 Project Grant award from the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837) will be used by The Medical College of Wisconsin, Inc. to establish a large patient cohort leveraging electronic health record and administrative claims data to determine the risks of cardiopulmonary and renal end organ complications and factors associated with frequent acute care use among individuals with sickle cell disease. The award period...
- The federal Project Grant award in the amount of $503,870.00 was provided by the National Heart, Lung, and Blood Institute (CFDA Program 93.837 - Cardiovascular Diseases Research) to Drexel University. The award is focused on developing a mechanistic understanding of how fetal hemoglobin (HbF) modulates the polymerization of sickle cell hemoglobin (HbS), which is the root cause of sickle cell disease. The research aims to address critical knowledge gaps that limit the rational optimization of...
This Project Grant award, funded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), is supporting research to assess the feasibility, acceptability, and safety of using methylphenidate to address executive functioning impairment in pediatric patients with sickle cell disease. The $277,500 award to St. Jude Children's Research Hospital Inc. will fund a 2-year study to: 1) assess the feasibility, acceptability, and adherence to methylphenidate treatment; 2) measure key neurobehavioral and safety outcomes; and 3) evaluate decision-making and determinants influencing methylphenidate utilization among parents. The research aims to address the debilitating neurocognitive dysfunction experienced by children and adolescents with sickle cell disease, with the goal of improving their academic performance, healthcare transitions, and overall quality of life.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $277.5k | 7/28/25 |